Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy

CD44v6 is overexpressed in a variety of cancers,rendering it a promising target for radio-immunotherapy (RIT).In this study, we have characterized a novel engineered recombinantmonoclonal anti-CD44 ...